Antoine Cortot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2906423/publications.pdf

Version: 2024-02-01

8138 19608 22,666 163 61 148 citations h-index g-index papers 171 171 171 15736 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	2.4	80
2	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 533-541.	1.9	35
3	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	6.1	24
4	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. Journal of Crohn's and Colitis, 2017, 11, 1326-1334.	0.6	19
5	Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk. International Journal of Colorectal Disease, 2017, 32, 453-458.	1.0	11
6	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 252-261.	1.9	111
7	Mo1899 Evaluation and Long-Term Benefit of Deep Remission in Crohn's Disease Patients Treated With Infliximab. Gastroenterology, 2016, 150, S810-S811.	0.6	1
8	Mo1900 Combination Therapy With Infliximab and Methotrexate Does Not Improve Crohn's Disease Outcome and Infliximab Tolerance Compared to Infliximab Therapy Alone. Gastroenterology, 2016, 150, S811.	0.6	0
9	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. Journal of Crohn's and Colitis, 2016, 11, jjw151.	0.6	17
10	Mo 1898 Continuation or Switch to Another Anti-TNFÎ \pm After Intestinal Resection in Crohn's Disease Patients Previously Exposed to Anti-TNFÎ \pm ?. Gastroenterology, 2016, 150, S810.	0.6	0
11	Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case–Control and Cohort Studies. Clinical Gastroenterology and Hepatology, 2015, 13, 1405-1415.e1.	2.4	23
12	Eosinophilic Enteritis. Digestive Diseases, 2015, 33, 183-189.	0.8	22
13	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunology, 2014, 7, 589-601.	2.7	78
14	Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study , ,. American Journal of Clinical Nutrition, 2014, 100, 850-858.	2.2	14
15	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut, 2014, 63, 423-432.	6.1	282
16	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 2014, 63, 1416-1423.	6.1	122
17	Efficacy of sacral nerve stimulation for poor functional results of J-pouch ileoanal anastomosis. Techniques in Coloproctology, 2014, 18, 355-360.	0.8	10
18	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. American Journal of Physiology - Renal Physiology, 2014, 307, G274-G285.	1.6	60

#	Article	IF	Citations
19	Long-term Outcome After First Intestinal Resection in Pediatric-onset Crohnʽs Disease. Inflammatory Bowel Diseases, 2013, 19, 7-14.	0.9	38
20	Space-time clusters of Crohn's disease in northern France. Zeitschrift Fur Gesundheitswissenschaften, 2013, 21, 497-504.	0.8	12
21	Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 286-292.	2.4	420
22	Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD). Digestive and Liver Disease, 2013, 45, 89-94.	0.4	157
23	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARÎ ³ . Carcinogenesis, 2013, 34, 2580-2586.	1.3	30
24	Portomesenteric Vein Thrombosis in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 582-589.	0.9	39
25	Colonic Inflammation in Mice Is Improved by Cigarette Smoke through iNKT Cells Recruitment. PLoS ONE, 2013, 8, e62208.	1.1	30
26	Better Outcome of Patients Undergoing Enteral Tube Feeding After Myeloablative Conditioning for Allogeneic Stem Cell Transplantation. Transplantation, 2012, 94, 287-294.	0.5	90
27	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2063-2071.	0.9	96
28	Clinical predictors at diagnosis of disabling pediatric Crohn $\hat{E}\frac{1}{4}$ s disease. Inflammatory Bowel Diseases, 2012, 18, 2072-2078.	0.9	32
29	AIEC colonization and pathogenicity: Influence of previous antibiotic treatment and preexisting inflammation. Inflammatory Bowel Diseases, 2012, 18, 1923-1931.	0.9	35
30	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut, 2011, 60, 198-203.	6.1	160
31	Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology, 2011, 140, 1785-1794.e4.	0.6	1,718
32	Stevens–Johnson syndrome with sulfasalazine treatment: Report of two cases. Journal of Crohn's and Colitis, 2011, 5, 457-460.	0.6	18
33	Early Surgery is Not Associated With Poor Prognosis in Pediatric Crohn's Disease: A Population-Based Study. Gastroenterology, 2011, 140, S-38.	0.6	2
34	Natural History of Eosinophilic Gastroenteritis. Clinical Gastroenterology and Hepatology, 2011, 9, 950-956.e1.	2.4	171
35	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1621-1628.e5.	0.6	431
36	Clinical Course of Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis: Results of a National Multicentre Study. Gastroenterology, 2011, 140, S-776.	0.6	0

#	Article	IF	CITATIONS
37	The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10-to 19-year-old age bracket (1988-2007). Alimentary Pharmacology and Therapeutics, 2011, 33, 1133-1142.	1.9	138
38	Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A population-based study. Inflammatory Bowel Diseases, 2011, 17, 2144-2152.	0.9	87
39	Efficacy of Diosmectite (Smecta) \hat{A}^{\otimes} /sup>in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study. Gastroenterology Research and Practice, 2011, 2011, 1-8.	0.7	23
40	A fulminant colitis index greater or equal to 8Âis not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroenterologie Clinique Et Biologique, 2010, 34, 612-617.	0.9	2
41	Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory Bowel Diseases, 2010, 16, 233-242.	0.9	187
42	Mapping of inflammatory bowel disease in northern France: Spatial variations and relation to affluence. Inflammatory Bowel Diseases, 2010, 16, 807-812.	0.9	30
43	Thiopurine S-methyltransferase deficiency associated with a novel mutation. Inflammatory Bowel Diseases, 2010, 16, 1821-1822.	0.9	0
44	The efficacy and safety of a third anti‶NF monoclonal antibody in Crohn's disease after failure of two other anti‶NF antibodies. Alimentary Pharmacology and Therapeutics, 2010, 31, 92-101.	1.9	108
45	Preâ€operative management is associated with low rate of postâ€operative morbidity in penetrating Crohn's disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 459-465.	1.9	78
46	Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study. American Journal of Gastroenterology, 2010, 105, 1893-1900.	0.2	128
47	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy. Clinical Gastroenterology and Hepatology, 2010, 8, 1048-1055.	2.4	158
48	S2002 Predictors of Poor Outcome in Pediatric Crohn's Disease. Gastroenterology, 2010, 138, S-298-S-299.	0.6	0
49	The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study. American Journal of Gastroenterology, 2009, 104, 2080-2088.	0.2	273
50	Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases, 2009, 15, 1044-1048.	0.9	54
51	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with CrohnÊ⅓s disease. Inflammatory Bowel Diseases, 2009, 15, 1476-1484.	0.9	59
52	114 The Changing Pattern of Crohn's Disease Incidence According to Age in Northern France: A Constant Increase in the 0-19 Year's Age Group (1988-2005). Gastroenterology, 2009, 136, A-20.	0.6	1
53	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	6.3	996
54	Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse. Clinical Gastroenterology and Hepatology, 2009, 7, 80-85.	2.4	152

#	Article	IF	CITATIONS
55	Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Alimentary Pharmacology and Therapeutics, 2008, 28, 984-993.	1.9	36
56	Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study. Gastroenterology, 2008, 135, 1106-1113.	0.6	549
57	Mesalamine Foam Enema <i>Versus</i> Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 3106-3114.	0.2	56
58	Familial Crohn's Disease in Belgium. Journal of Clinical Gastroenterology, 2007, 41, 583-590.	1.1	18
59	Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case–Control Study. American Journal of Gastroenterology, 2007, 102, 122-131.	0.2	109
60	Épidémiologie et facteurs de risque des maladies inflammatoires chroniques de l'intestin. Bulletin De L'Academie Nationale De Medecine, 2007, 191, 1105-1123.	0.0	11
61	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Alimentary Pharmacology and Therapeutics, 2006, 24, 851-858.	1.9	32
62	Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. Gastroenterologie Clinique Et Biologique, 2006, 30, 594-597.	0.9	67
63	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 2006, 55, i16-i35.	6.1	533
64	Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population-Based Study in Northern France (1988-1999). Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 49-55.	0.9	195
65	Environmental Factors in Familial Crohn's Disease in Belgium. Inflammatory Bowel Diseases, 2005, 11, 360-365.	0.9	69
66	Pneumocystis jiroveci (carinii) Pneumonia After Initiation of Infliximab and Azathioprine Therapy in a Patient with Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 2005, 11, 618-620.	0.9	24
67	Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut, 2005, 54, 357-363.	6.1	203
68	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ. Journal of Experimental Medicine, 2005, 201, 1205-1215.	4.2	428
69	Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut, 2004, 53, 843-848.	6.1	214
70	Pneumocystis Jiroveci (Carinii) Pneumonia Following Initiation of Infliximab and Azathioprine Therapy in a Patient With Crohn $\hat{E}^{1}/4$ s Disease. Inflammatory Bowel Diseases, 2004, 10, 436-437.	0.9	44
71	Probiotics in inflammatory bowel disease: a critical review. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 805-820.	1.0	60
72	Increased incidence of crohn's disease in children in Northern France. Results of a prospective population-based study (1988È 1999). Gastroenterology, 2003, 124, A208.	0.6	0

#	Article	IF	CITATIONS
73	A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology, 2003, 124, A62.	0.6	31
74	Echoendoscopy modifies classical predictive criteria of a biliary origin of acute pancreatitis: Prospective multicentre french study. Gastroenterology, 2003, 124, A84.	0.6	0
75	Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease. Gastroenterology, 2003, 124, A192-A193.	0.6	8
76	A randomised placebo controlled trial of pegylated interferon \hat{A} in active ulcerative colitis. Gut, 2003, 52, 1728-1733.	6.1	78
77	What are the major arguments in favour of the genetic susceptibility for inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2003, 15, 587-592.	0.8	18
78	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. American Journal of Gastroenterology, 2002, 97, 939-946.	0.2	240
79	Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. American Journal of Gastroenterology, 2002, 97, 649-653.	0.2	26
80	Inflammatory bowel disease in spouses and their offspring. Gastroenterology, 2001, 120, 816-819.	0.6	109
81	Effect of switching to budesonide on the quality of life of patients with steroid-dependent Crohn's disease. Gastroenterology, 2001, 120, A748.	0.6	0
82	Azathioprine (AZA) for ulcerative coltis: A retrospective multicente study on 131 patients. Gastroenterology, 2001, 120, A625-A626.	0.6	5
83	Safety of switching systemic steroids to budesonide modified-release capsules in steroid-dependent patients with inactive Crohn's disease. Gastroenterology, 2001, 120, A749.	0.6	0
84	The Importance of Familial Clusterings in Crohn's Disease. Inflammatory Bowel Diseases, 2001, 7, 170-173.	0.9	4
85	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001, 411, 599-603.	13.7	5,088
86	Genetically related Escherichia coli strains associated with Crohn's disease. Gut, 2001, 48, 320-325.	6.1	87
87	Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut, 2001, 48, 186-190.	6.1	89
88	Antibiotics in Crohn's disease. Gut, 2001, 48, 647-647.	6.1	26
89	Familial and Sporadic Inflammatory Bowel Disease: Different Entities?. Inflammatory Bowel Diseases, 2000, 6, 314-320.	0.9	26
90	Pouchitis Is Associated with Mucosal Imbalance Between Interleukin-8 and Interleukin-10. Inflammatory Bowel Diseases, 2000, 6, 157-164.	0.9	42

#	Article	IF	Citations
91	Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): No relationship with disease activity. Inflammatory Bowel Diseases, 2000, 6, 270-274.	0.9	34
92	Familial and sporadic inflammatory bowel disease: Different entities?. Inflammatory Bowel Diseases, 2000, 6, 314-320.	0.9	34
93	Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 2000, 118, A342.	0.6	4
94	Virus Serology in Familial Crohn Disease. Scandinavian Journal of Gastroenterology, 2000, 35, 403-407.	0.6	10
95	Methotrexate in Crohn's Disease: Long-Term Efficacy and Toxicity. American Journal of Gastroenterology, 2000, 95, 1730-1734.	0.2	57
96	An evaluation of the effects of budesonide and mesalamine on the clinical condition of patients with active Crohn's disease. Gastroenterology, 2000, 118, A782.	0.6	0
97	A comparison of the effect of budesonide and mesalamine on quality-of-life in patients with active Crohn's disease. Gastroenterology, 2000, 118, A783.	0.6	0
98	Low ileal IL-10 mRNA levels predict endoscopic recurrence in patients operated on for Crohn's disease (CD). Gastroenterology, 2000, 118, A108-A109.	0.6	0
99	Infectious agents and Crohn's disease. Clinical Microbiology and Infection, 1999, 5, 601-604.	2.8	9
100	Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology, 1999, 116, 294-300.	0.6	284
101	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology, 1999, 117, 73-81.	0.6	305
102	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn $\hat{E}^{1}\!\!/4$ s disease. European Journal of Gastroenterology and Hepatology, 1999, 11, 1113-1120.	0.8	17
103	Transdermal Nicotine Decreases Mucosal IL-8 Expression but Has No Effect on Mucin Gene Expression in Ulcerative Colitis. Inflammatory Bowel Diseases, 1999, 5, 174-181.	0.9	20
104	Similar IL-5, IL-3, and GM-CSF Syntheses by Eosinophils in the Jejunal Mucosa of Patients with Celiac Disease and Dermatitis Herpetiformis. Clinical Immunology and Immunopathology, 1998, 88, 14-21.	2.1	35
105	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 1998, 115, 1405-1413.	0.6	767
106	Cell-Free Whey from Milk Fermented with Bifidobacterium breve C50 Used to Modify the Colonic Microflora of Healthy Subjects. Journal of Dairy Science, 1998, 81, 1229-1235.	1.4	59
107	No bacteria detected by PCR in mesenteric lymph nodes from patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A944-A945.	0.6	0
108	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). Gastroenterology, 1998, 114, A958-A959.	0.6	5

#	Article	IF	CITATIONS
109	Stratification of Crohn's disease by anti Saccharomyces cerevisiae mannan antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA). Gastroenterology, 1998, 114, A950.	0.6	1
110	Is endoscopic ultrasonography helpful before ERCP in the management of patients at risk of biliary obstruction?. Gastroenterology, 1998, 114, A530.	0.6	0
111	Mesenteric obesity in Crohn's disease (CD). Gastroenterology, 1998, 114, A989.	0.6	1
112	Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD). Gastroenterology, 1998, 114, A1038.	0.6	1
113	A Comparison of Budesonide and Mesalamine for Active Crohn's Disease. New England Journal of Medicine, 1998, 339, 370-374.	13.9	330
114	Anti- Saccharomyces cerevisiae Mannan Antibodies in Familial Crohn's Disease. American Journal of Gastroenterology, 1998, 93, 1306-1310.	0.2	146
115	Anti- <i>Saccharomyces cerevisiae</i> i> mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut, 1998, 42, 788-791.	6.1	568
116	Anticipation in familial Crohn's disease. Gut, 1998, 42, 170-174.	6.1	63
117	Mixed Adenocarcinoid Tumor and Crohn's Disease. Journal of Clinical Gastroenterology, 1998, 26, 353-354.	1.1	8
118	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology, 1997, 113, 118-126.	0.6	212
119	Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Digestive Diseases and Sciences, 1997, 42, 817-822.	1.1	201
120	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology, 1996, 110, 768-774.	0.6	158
121	Clinical characteristics of Crohn's disease in 72 families. Gastroenterology, 1996, 111, 604-607.	0.6	177
122	Differentiation and identification of human faecal anaerobic bacteria producing Î ² -galactosidase (a new) Tj ETQq	0 0 0 rgBT	/Overlock 10
123	Chronic pancreatitis: a complication of sarcoidosis?. European Journal of Gastroenterology and Hepatology, 1996, 8, 1125-1127.	0.8	10
124	Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. European Journal of Gastroenterology and Hepatology, 1996, 8, 229-234.	0.8	95
125	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. Clinical and Experimental Immunology, 1996, 104, 293-296.	1.1	2
126	Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature, 1996, 379, 821-823.	13.7	906

#	Article	IF	Citations
127	Interferon-î± in combination with corticosteroids improves systemic mast cell disease. British Journal of Dermatology, 1995, 132, 479-482.	1.4	58
128	Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Digestive Diseases and Sciences, 1995, 40, 2641-2646.	1.1	45
129	Hyperbaric oxygenation in severe perineal Crohn's disease. Diseases of the Colon and Rectum, 1995, 38, 609-614.	0.7	68
130	Biofeedback for the treatment of fecal incontinence. Diseases of the Colon and Rectum, 1995, 38, 393-397.	0.7	89
131	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease Gut, 1995, 37, 242-246.	6.1	100
132	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis Gut, 1995, 37, 132-135.	6.1	6
133	Low prevalence of gastric infection by Helicobacter pylori (HP) during long term treatment of esophagitis with omeprazole. Gastroenterology, 1995, 108, A60.	0.6	0
134	Influence of the degree of severity of fundic gastritis on serum gastrin concentration and ECL cell density in controls and during prolonged treatment with antisecretory drugs. Gastroenterology, 1995, 108, A83.	0.6	0
135	European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. Gastroenterology, 1995, 109, 774-782.	0.6	156
136	Immunocytochemical evidence of Listeria, Escherichia coil, and Streptococcus antigens in Crohn's disease. Gastroenterology, 1995, 108, 1396-1404.	0.6	287
137	lgM-specific measles-virus antibody in families with a high frequency of Crohn's disease. Lancet, The, 1995, 346, 967.	6.3	12
138	Visual evoked potentials, electroretinogram and neuropsychological evaluation in malnutrition. Gastroenterology, 1995, 108, A721.	0.6	0
139	Serosal vascular lesions in Crohn's disease. Gastroenterology, 1995, 108, A808.	0.6	0
140	Density of fundic ECL cells during long term treatment of reflux esophagitis by omeprazole or histamine H2-receptor antagonists. Gastroenterology, 1995, 108, A266.	0.6	0
141	Incidence of inflammatory bowel disease in northern France (1988-1990) Gut, 1994, 35, 1433-1438.	6.1	215
142	Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liege county of Belgium Gut, 1994, 35, 1316-1318.	6.1	40
143	Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives Gut, 1994, 35, 231-235.	6.1	382
144	Cap polyposis occurring in the postoperative course of pelvic surgery Gut, 1994, 35, 1670-1672.	6.1	39

#	Article	IF	CITATIONS
145	Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease. American Journal of Medical Genetics Part A, 1994, 52, 207-213.	2.4	42
146	Severe acute pancreatitis following laser treatment of periampullary villous adenoma. Digestive Diseases and Sciences, 1993, 38, 382-383.	1.1	2
147	Action of in situ nitroglycerin on upper anal canal pressure of patients with terminal constipation. Diseases of the Colon and Rectum, 1993, 36, 372-376.	0.7	38
148	Perioperative endoscopy of the whole small bowel in Crohn's disease Gut, 1993, 34, 647-649.	6.1	68
149	Intestinal involvement in sarcoidosis. Gastroenterology, 1993, 104, 947.	0.6	2
150	Anti-Neutrophil Cytoplasmic Auto-Antibodies (ANCA) in Patients with Ulcerative Colitis (UC): Influence of Disease Activity and Familial Study. Advances in Experimental Medicine and Biology, 1993, 336, 515-518.	0.8	15
151	Effect of intrajejunal elemental diet perfusion on jejunal secretion of immunoglobulins, albumin, and hyaluronan in man Gut, 1992, 33, 44-47.	6.1	7
152	Increased pulmonary and intestinal permeability in Crohn's disease Gut, 1992, 33, 678-682.	6.1	63
153	Molecular form of faecal alpha 1 antitrypsin in patients with Crohn's disease Gut, 1992, 33, 572-572.	6.1	0
154	Activated eosinophils in adult coeliac disease: evidence for a local release of major basic protein Gut, 1992, 33, 1190-1194.	6.1	49
155	Endoscopic palliation for inoperable malignant dysphagia: long term follow up Gut, 1992, 33, 1602-1607.	6.1	24
156	Endoscopic Laser Treatment for Rectosigmoid Villous Adenoma: Factors Affecting the Results. Canadian Journal of Gastroenterology & Hepatology, 1992, 6, 301-307.	1.8	0
157	Nitroglycerinin situ reduces upper anal canal pressure. Digestive Diseases and Sciences, 1992, 37, 155-155.	1.1	14
158	Oxidative and synthetic functions of n-butyrate in colonocytes. Diseases of the Colon and Rectum, 1992, 35, 511-512.	0.7	12
159	Bipolar electrocoagulation treatment for hemorrhagic radiation injury of the lower digestive tract. Gastrointestinal Endoscopy, 1991, 37, 492-493.	0.5	28
160	Deglycosylation of $\hat{l}\pm 1$ -proteinase inhibitor is impaired in the faeces of patients with active inflammatory bowel disease (Crohn's disease). Clinical Science, 1991, 80, 517-523.	1.8	8
161	Treatment of diversion colitis by short-chain fatty acids. Diseases of the Colon and Rectum, 1991, 34, 861-864.	0.7	128
162	Functional assessment of coloanal anastomosis with reservoir and excision of the anal transition zone. Diseases of the Colon and Rectum, 1991, 34, 967-972.	0.7	27

ANTOINE CORTOT

#	Article	IF	CITATIONS
163	Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Gastroenterology, 1990, 98, 811-818.	0.6	698